CL2012001271A1 - Combinacion que comprende un inhibidor de smoothened que es 2-(r)-4-(6-bencil-4,5-dimetil-piridazin-3-il)-2-metil-3,4,5,6-tetrahidro-2h-[1,2`]-bipirazinil-5`-il]-propan-2-ol y un inhibidor de mtor; uso para tratar el cancer. - Google Patents

Combinacion que comprende un inhibidor de smoothened que es 2-(r)-4-(6-bencil-4,5-dimetil-piridazin-3-il)-2-metil-3,4,5,6-tetrahidro-2h-[1,2`]-bipirazinil-5`-il]-propan-2-ol y un inhibidor de mtor; uso para tratar el cancer.

Info

Publication number
CL2012001271A1
CL2012001271A1 CL2012001271A CL2012001271A CL2012001271A1 CL 2012001271 A1 CL2012001271 A1 CL 2012001271A1 CL 2012001271 A CL2012001271 A CL 2012001271A CL 2012001271 A CL2012001271 A CL 2012001271A CL 2012001271 A1 CL2012001271 A1 CL 2012001271A1
Authority
CL
Chile
Prior art keywords
inhibitor
bipyrazinyl
pyridazin
propan
tetrahydro
Prior art date
Application number
CL2012001271A
Other languages
English (en)
Spanish (es)
Inventor
Silvia Buonamici
Marion Dorsch
Echeverria Carlos Garcia
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43384585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001271(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2012001271A1 publication Critical patent/CL2012001271A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2012001271A 2009-11-18 2012-05-16 Combinacion que comprende un inhibidor de smoothened que es 2-(r)-4-(6-bencil-4,5-dimetil-piridazin-3-il)-2-metil-3,4,5,6-tetrahidro-2h-[1,2`]-bipirazinil-5`-il]-propan-2-ol y un inhibidor de mtor; uso para tratar el cancer. CL2012001271A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26234209P 2009-11-18 2009-11-18
US29203210P 2010-01-04 2010-01-04

Publications (1)

Publication Number Publication Date
CL2012001271A1 true CL2012001271A1 (es) 2012-10-12

Family

ID=43384585

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001271A CL2012001271A1 (es) 2009-11-18 2012-05-16 Combinacion que comprende un inhibidor de smoothened que es 2-(r)-4-(6-bencil-4,5-dimetil-piridazin-3-il)-2-metil-3,4,5,6-tetrahidro-2h-[1,2`]-bipirazinil-5`-il]-propan-2-ol y un inhibidor de mtor; uso para tratar el cancer.

Country Status (18)

Country Link
US (2) US20120232087A1 (enExample)
EP (1) EP2501370A1 (enExample)
JP (1) JP2013511526A (enExample)
KR (1) KR20120107962A (enExample)
CN (2) CN104224791A (enExample)
AU (1) AU2010322114B2 (enExample)
BR (1) BR112012011823A2 (enExample)
CA (1) CA2781210A1 (enExample)
CL (1) CL2012001271A1 (enExample)
IL (1) IL219636A0 (enExample)
MA (1) MA33739B1 (enExample)
MX (1) MX2012005695A (enExample)
NZ (1) NZ599964A (enExample)
PH (1) PH12012500911A1 (enExample)
RU (1) RU2012125152A (enExample)
TN (1) TN2012000205A1 (enExample)
WO (1) WO2011062939A1 (enExample)
ZA (1) ZA201203325B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012125070A (ru) 2009-11-18 2013-12-27 Плексксикон, Инк. Соединения и способы модулирования киназы и показания к их применению
WO2012166241A1 (en) * 2011-06-02 2012-12-06 Novartis Ag Biomarkers for hedgehog inhibitor therapy
WO2013106812A1 (en) * 2012-01-12 2013-07-18 Board Of Regents, The University Of Texas System Personalized medicine for the prediction of therapy targeting the hedgehog pathway
US9499539B2 (en) * 2012-11-05 2016-11-22 Nantbioscience, Inc. Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway
CN103524535B (zh) * 2013-10-16 2016-07-13 苏州云轩医药科技有限公司 具有刺猬通路拮抗剂活性的胺基噻唑-吡啶杂环化合物
IL302385B2 (en) 2017-01-06 2024-06-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
LT3786160T (lt) 2017-10-27 2022-09-26 Boehringer Ingelheim International Gmbh Piridino dariniai ir jų terapinis panaudojimas kaip trpc6 inhibitorių
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
WO2020061584A1 (en) * 2018-09-21 2020-03-26 Msb Holdings, Inc. Taste-masked dosage forms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
EP1954699B1 (en) 2005-11-22 2012-09-19 Kudos Pharmaceuticals Ltd PYRIDO-, PYRAZO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
RS55881B1 (sr) 2006-08-23 2017-08-31 Kudos Pharm Ltd 2-metilmorfolin pirido-,pirazo- i pirimido-pirimidin derivati kao inhibitori mtor-a
BRPI0809193A2 (pt) * 2007-03-15 2014-09-23 Novartis Ag Compostos orgânicos e seus usos
WO2008154259A1 (en) * 2007-06-07 2008-12-18 Irm Llc Biphenylcarboxamide derivatives as hedgehog pathway modulators
EP2170866B1 (en) * 2007-06-25 2014-08-13 Amgen Inc. Phthalazine compounds, compositions and methods of use
EP2249844A1 (en) * 2008-03-12 2010-11-17 Ludwig-Maximilians-Universität München Active substance combination with gemcitabine for the treatment of epithelial cancer
UA102250C2 (ru) * 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors

Also Published As

Publication number Publication date
ZA201203325B (en) 2013-01-30
NZ599964A (en) 2014-08-29
PH12012500911A1 (en) 2012-11-26
IL219636A0 (en) 2012-07-31
CA2781210A1 (en) 2011-05-26
JP2013511526A (ja) 2013-04-04
CN102665700A (zh) 2012-09-12
AU2010322114A1 (en) 2012-05-31
MA33739B1 (fr) 2012-11-01
AU2010322114B2 (en) 2014-07-31
CN104224791A (zh) 2014-12-24
BR112012011823A2 (pt) 2019-09-24
RU2012125152A (ru) 2013-12-27
MX2012005695A (es) 2012-06-13
TN2012000205A1 (en) 2013-12-12
US20120232087A1 (en) 2012-09-13
EP2501370A1 (en) 2012-09-26
US20150025074A1 (en) 2015-01-22
KR20120107962A (ko) 2012-10-04
WO2011062939A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
CL2012001271A1 (es) Combinacion que comprende un inhibidor de smoothened que es 2-(r)-4-(6-bencil-4,5-dimetil-piridazin-3-il)-2-metil-3,4,5,6-tetrahidro-2h-[1,2`]-bipirazinil-5`-il]-propan-2-ol y un inhibidor de mtor; uso para tratar el cancer.
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
CL2012003643A1 (es) Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension.
CO6842016A2 (es) Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
CL2008000510A1 (es) Compuestos conjugados farmaco-ligandos, que se unen a citotoxinas potentes; composicion farmaceutica; y uso para retardar o detener el crecimiento de un tumor en un mamifero.
CL2014001062A1 (es) Metodo para tratar tumores del estroma gastrointestinal que comprende el uso de un inhibidor de c-hit y un inhibidor de pi3k o fgfr y combinacion que comprende a los compuestos.
CL2008001038A1 (es) Uso de una composicion que comprende un antagonosta h1, y un compuesto anti-tnf alfa para tratar conjuntivitis alegica o rinitis alergiva en un sujeto humano
CL2015000294A1 (es) Combinaciones farmaceuticas que comprenden un inhibidor de b-raf, un inhibidor del receptor del factor de crecimiento epidermico y opcionalmente un inhibidor pi3halpha y uso en el tratamiento de una enfermedad proliferativa.
DK2139483T3 (da) Kombinationsterapier, der omfatter en quinoxalin-inhibitor af PI3K-alfa, til anvendelse til behandling af cancer
BRPI0807717A2 (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
HRP20160551T8 (hr) Kombinirana terapija s pripravcima nanočestica taksana i hedgehog inhibitora
NO20090079L (no) Arylsulfonamider med analgesisk virkning
CL2013001324A1 (es) Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0822012A2 (pt) Derivados de quinazolina de 6,7-dialcóxi úteis para o tratamento de distúrbios relacionados com câncer
BRPI0909818A2 (pt) métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos
BRPI0913175A2 (pt) artigo antibalístico, e, uso do mesmo.
CL2008000110A1 (es) Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos.
BR112012004851A2 (pt) agente para o tratamento e/ou profilaxia de um distúrbio de humor, derivado de tiazol, e, uso do derivado de tiazol
CL2013002905A1 (es) Composición farmacéutica que comprende fimasartan, una sal, solvato o hidrato del mismo y amlodipina, un isómero, sal, solvato o hidrato del mismo; uso en el tratamiento de hipertensión y enfermedades cardiovasculares.
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
CL2015001564A1 (es) Composición que comprende una triazina y su uso en el tratamiento intramuscular de coccidiosis o enfermedad protozoaria relacionada, en un mamífero no humano.